Janux Therapeutics News

Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)

TipRanksMay 13 09:40 ET

Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 13 07:28 ET

Express News | HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $63

BenzingaMay 13 07:18 ET

Buy Rating Affirmed for Janux Therapeutics With Revised Higher Price Target Amidst Strong Financials and Promising Clinical Trials

TipRanksMay 13 06:21 ET

Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald

Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald

Dow JonesMay 9 10:30 ET

Express News | Cantor Fitzgerald Reiterates Overweight on Janux Therapeutics, Maintains $100 Price Target

BenzingaMay 9 10:20 ET

We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate

Yahoo FinanceMay 9 08:30 ET

Janux Therapeutics: Promising Early Data for EGFR-Targeted Therapies Warrants a Buy Rating

TipRanksMay 9 08:05 ET

Insiders Made Right Decision To Sell As Janux Therapeutics Dips 11%

Insiders seem to have made the most of their holdings by selling US$1.3m worth of Janux Therapeutics, Inc. (NASDAQ:JANX) stock at an average sell price of US$45.94 during the past year. The company's

Simply Wall StMay 9 07:35 ET

Janux Therapeutics | 10-Q: Quarterly report

Futu NewsMay 8 15:42 ET · Announcements

Janux Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results.

Janux Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results.

BenzingaMay 8 13:04 ET

Express News | Janux Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results

BenzingaMay 8 13:04 ET

Janux Therapeutics Price Target Raised to $74.00/Share From $53.00 by Wedbush

Janux Therapeutics Price Target Raised to $74.00/Share From $53.00 by Wedbush

Dow JonesMay 8 10:53 ET

Janux Therapeutics Is Maintained at Outperform by Wedbush

Janux Therapeutics Is Maintained at Outperform by Wedbush

Dow JonesMay 8 10:53 ET

Express News | Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $74

BenzingaMay 8 10:43 ET

Janux Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 35.94% Wedbush $53 → $74 Maintains Outperform 04/16/2024 28.59% JonesTrading → $70 Initiates Co

BenzingaMay 8 10:41 ET

Express News | Janux Therapeutics - Sales Agreement Prospectus Covers Offering of up to $150 Mln of Common Stock That May Be Issued and Sold From Time to Time

ReutersMay 8 09:17 ET

Express News | Janux Therapeutics Inc Files For Mixed Shelf

BenzingaMay 8 09:16 ET

Express News | Janux Therapeutics Inc Files for Mixed Shelf - SEC Filing

ReutersMay 8 09:15 ET

Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating

Janux Therapeutics (JANX) has an average rating of buy and price targets ranging from $25 to $100, according to analysts polled by Capital IQ. Price: 63.62, Change: +2.12, Percent Change: +3.45

MT NewswiresMay 8 09:06 ET